<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03996447</url>
  </required_header>
  <id_info>
    <org_study_id>GDX-44-010</org_study_id>
    <nct_id>NCT03996447</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Gadopiclenol for Central Nervous System (CNS) Magnetic Resonance Imaging (MRI)</brief_title>
  <acronym>PICTURE</acronym>
  <official_title>Efficacy and Safety of Gadopiclenol for Central Nervous System (CNS) Magnetic Resonance Imaging (MRI)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Guerbet</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Guerbet</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      the trial aims to evaluate the Efficacy and Safety of gadopiclenol for Central Nervous System&#xD;
      (CNS) Magnetic Resonance Imaging (MRI)&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this trial is to evaluate a new gadolinium-based contrast agent (GBCA)&#xD;
      gadopiclenol injection for Central Nervous System (CNS) lesion detection and visualization by&#xD;
      conventional steady-state CNS imaging. .&#xD;
&#xD;
      This is a multi-center, international, prospective, double-blind, randomized,&#xD;
      controlled,cross-over with comparator trial in male and female patients presenting with known&#xD;
      or highly suspected CNS lesion(s) with focal areas of disrupted Blood Brain Barrier (BBB)&#xD;
      (e.g., primary and secondary tumors) who are scheduled to undergo a routine contrast-enhanced&#xD;
      Magnetic Resonance Imaging (MRI) of the CNS.&#xD;
&#xD;
      This trial will be conducted in approximately 40 centers worldwide.&#xD;
&#xD;
      During the course of the trial, two MRIs will be obtained from each patient: one unenhanced&#xD;
      and gadopiclenol-enhanced MRI; and one unenhanced and gadobutrol-enhanced MRI. MRI&#xD;
      evaluations will be performed by on-site investigators and three independent off-site blinded&#xD;
      readers.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 3, 2019</start_date>
  <completion_date type="Actual">September 11, 2020</completion_date>
  <primary_completion_date type="Actual">September 11, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>lesion visualization criteria for gadopiclenol-enhanced MRI compared to unenhanced MRI</measure>
    <time_frame>1 day procedure</time_frame>
    <description>The lesion visualization criteria is based on 3 co-primary criteria: border delineation, internal morphology and degree of contrast enhancement, assessed on the images acquired during the MRI performed with gadopiclenol by independent readers for the 3 most representative lesions.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Lesion visualization criteria for gadopiclenol compared to gadobutrol</measure>
    <time_frame>1 day procedure</time_frame>
    <description>the lesion visualization criteria is based on 3 co-primary criteria: border delineation, internal morphology and degree of contrast enhancement assessed on the images acquired during the MRI performed with gadopiclenol and those performed with gadobutrol.&#xD;
For each reader, only matching lesion between paired images of gadobutrol and gadopiclenol will be considered</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">260</enrollment>
  <condition>CNS Lesion</condition>
  <condition>Blood Brain Barrier Defect</condition>
  <arm_group>
    <arm_group_label>gadopiclenol-enhanced MRI then gadobutrol-enhanced MRI</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>cross-over design. each patient will receive gadopiclenol for the first MRI and gadobutrol for the second MRI</description>
  </arm_group>
  <arm_group>
    <arm_group_label>gadobutrol-enhanced MRI then gadopiclenol-enhanced MRI</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>cross-over design. each patient will receive gadobutrol for the first MRI and gadopiclenol for the second MRI</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gadopiclenol</intervention_name>
    <description>single intravenous (IV) bolus injection at a rate of 2ml/second</description>
    <arm_group_label>gadobutrol-enhanced MRI then gadopiclenol-enhanced MRI</arm_group_label>
    <arm_group_label>gadopiclenol-enhanced MRI then gadobutrol-enhanced MRI</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gadobutrol 1Mmol/mL Solution for Injection Vial</intervention_name>
    <description>single intravenous (IV) bolus injection at a rate of 2ml/second</description>
    <arm_group_label>gadobutrol-enhanced MRI then gadopiclenol-enhanced MRI</arm_group_label>
    <arm_group_label>gadopiclenol-enhanced MRI then gadobutrol-enhanced MRI</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient presenting with known or highly suspected CNS lesion(s) with focal areas of&#xD;
             disrupted Blood Brain Barrier (BBB) (e.g., primary and secondary tumors) based on&#xD;
             results of a previous imaging procedure such as Computed Tomography (CT) or MRI, which&#xD;
             should have been performed within 12 months prior to ICF signature.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient presenting with acute or chronic renal insufficiency, defined as an estimated&#xD;
             Glomerular Filtration Rate (eGFR) &lt; 30 mL/min/1.73 m² assessed within 1 day prior to&#xD;
             each contrast agent injection&#xD;
&#xD;
          -  Patient presenting extra cranial lesions and/or extra-dural lesions.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lorie Loevner, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pennsylvania</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>ASCLEPES Research Centers</name>
      <address>
        <city>Panorama City</city>
        <state>California</state>
        <zip>91402</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Connecticut Health Center</name>
      <address>
        <city>Farmington</city>
        <state>Connecticut</state>
        <zip>06030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern Memorial Hospital</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwest Neurology, Ltd.</name>
      <address>
        <city>Rolling Meadows</city>
        <state>Illinois</state>
        <zip>600008</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Missouri Hospital and Clinic</name>
      <address>
        <city>Columbia</city>
        <state>Missouri</state>
        <zip>65212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>South Carolina Clinical &amp; Translational Research (SCTR) Institute</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Of Washington - Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ZNA Middelheim</name>
      <address>
        <city>Antwerp</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UZ Brussel - Campus Jette</name>
      <address>
        <city>Brussel</city>
        <zip>1090</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU - Hôpital Roger Salengro - Neurologie</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Sainte-Anne</name>
      <address>
        <city>Paris</city>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU La Miletrie</name>
      <address>
        <city>Poitiers</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU Strasbourg Hôpital de Hautepierre</name>
      <address>
        <city>Strasbourg</city>
        <zip>67098</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uniklinik Mannheim</name>
      <address>
        <city>Mannheim</city>
        <zip>68167</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Semmelweis Egyetem - Neurology</name>
      <address>
        <city>Budapest</city>
        <zip>1083</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Orszagos Klinikai Idegtudomanyi Intezet</name>
      <address>
        <city>Budapest</city>
        <zip>1145</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Debreceni Egyetem Klinikai Kozpont</name>
      <address>
        <city>Debrecen</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pecsi Tudomanyegyetem Klinikai Kozpont - Idegsebeszeti Klinika</name>
      <address>
        <city>Pécs</city>
        <zip>Pécs</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Szegedi Tudomanyegyetem AOK</name>
      <address>
        <city>Szeged</city>
        <zip>6725</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ASL 1 Abruzzo Avezzano-Sulmona-L'Aquila, Ospedale Regionale San Salvatore</name>
      <address>
        <city>L'Aquila</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fondazione I.R.C.C.S. C.Mondino</name>
      <address>
        <city>Pavia</city>
        <zip>27100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Neurologico Mediterraneo-Neuromed, I.R.C.C.S.</name>
      <address>
        <city>Pozzilli</city>
        <zip>86077</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Sanitaria Universitaria Integrata di Trieste-PO Cattinara</name>
      <address>
        <city>Trieste</city>
        <zip>34149</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Konkuk University Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>05030</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>5505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Axis Heilsa S. de R.L. de C.V. (Althian)</name>
      <address>
        <city>Monterrey</city>
        <zip>64060</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Institute S.C</name>
      <address>
        <city>Tlalnepantla de Baz</city>
        <zip>54055</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uniwersyteckie Centrum Kliniczne w Gdańsku, Zakład Radiologii</name>
      <address>
        <city>Gdańsk</city>
        <zip>80-214</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital del Mar</name>
      <address>
        <city>Barcelona</city>
        <zip>08003</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>M.D. Anderson Cancer Center Madrid</name>
      <address>
        <city>Madrid</city>
        <zip>28033</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico San Carlos</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Taipei Veterans General Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>11217</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Korea, Republic of</country>
    <country>Mexico</country>
    <country>Poland</country>
    <country>Spain</country>
    <country>Taiwan</country>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>June 21, 2019</study_first_submitted>
  <study_first_submitted_qc>June 21, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 24, 2019</study_first_posted>
  <disposition_first_submitted>May 12, 2021</disposition_first_submitted>
  <disposition_first_submitted_qc>May 12, 2021</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">May 21, 2021</disposition_first_posted>
  <last_update_submitted>June 30, 2021</last_update_submitted>
  <last_update_submitted_qc>June 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

